Inovio Pharmaceuticals Q4 2023 GAAP EPS $(1.100) Beats $(1.270) Estimate, Sales $103.000K Miss $344.200K Estimate
Portfolio Pulse from Benzinga Newsdesk
Inovio Pharmaceuticals (NASDAQ:INO) reported Q4 2023 GAAP EPS of $(1.100), surpassing the $(1.270) estimate, but its sales of $103K fell short of the $344.2K estimate, marking a 17.60% decrease from the same period last year.
March 06, 2024 | 9:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Inovio Pharmaceuticals reported better-than-expected Q4 2023 EPS but missed sales estimates significantly, with a notable year-over-year decrease.
While the EPS beat might provide some positive sentiment, the significant miss on sales estimates and the year-over-year decrease in sales are likely to concern investors, potentially leading to a negative short-term impact on INO's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100